ClinicalTrials.gg
CompletedNCT05941247Updated Mar 1, 2024

A Study to Evaluate the Effects of Single and Multiple Doses of Hemay005 Tablets in Health Caucasian Adult Volunteers

A Phase 1 interventional study of Hemay005 60 mg in Healthy, sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to assess the safety and tolerability of single and multiple oral doses of Hemay005 tablets in healthy Caucasian adult volunteers.

Read the detailed description

This is a phase I, single-arm, open-label ethno-bridging study. The study is being conducted to test a potential new treatment for Behçet's disease (BD) called Hemay005.

The primary objective of this study is to evaluate the safety and tolerability of Hemay005 tablets after single and multiple oral doses in healthy Caucasian adult volunteers. The secondary objective of this study is to assess the pharmacokinetic parameters (time to remove the study drug from blood) of Hemay005 tablets after single and multiple oral doses.

The results of Chinese healthy volunteers will be used as a historical control to compare the ethnic differences between Chinese and Caucasians.

Approximately 12 eligible healthy (Caucasian) adult participants (male: female = 1:1) will be enrolled in this study.

The participant will be screened to determine their suitability to take part in the study within 28 days before receiving a dose of the study treatment. There will be one confinement period in the clinic, which will start on the day before dosing with dosing on Day 1 and discharge on Day 11. The participant will be asked to attend the clinic for a final study visit on Day 20. This visit will be the end of the participation in this study.

02

Conditions studied

  • Healthy

Keywords

  • PK parameters
  • Caucasian
03

In context

Lead sponsor

Ganzhou Hemay Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male or female Caucasian participants (male: female = 1:1) between 18 and 55 years of age (both inclusive) at the time of signing the .
  2. Body weight between 50 and 100 kg (both inclusive) for males or between 45 and 100 kg (both inclusive) for females; and (BMI) within 18-32 kg/m2 (both inclusive).
  3. In good health as determined by screening tests. Good health is defined as having no abnormalities identified by a detailed medical history, full physical examination, vital signs (including measurement of body temperature, HR, blood pressure and respiratory rate), 12-lead , and clinical laboratory tests.
  4. Female participants must not be pregnant or breastfeeding and must use an effective method from informed consent obtained to 180 days after last dose administration, with the exception of participants who have undergone sterilization in the preceding 3 months, or who are .

    A woman of (WOCBP) must undergo pregnancy testing prior to the first dose of the medicinal product (IMP). The participant must be excluded from the study if the serum pregnancy test is positive. A postmenopausal state is defined as 12 months of amenorrhea without an alternative medical cause. In the absence of 12 months of amenorrhea, menopause may be confirmed by follicle-stimulating hormone (FSH) measurement. Females on hormonal replacement therapy (HRT), where menopausal status is indeterminate, will be required to use a non-estrogen hormonal contraceptive method if they wish to continue their HRT during the study. Participants must otherwise discontinue HRT to allow for confirmation of postmenopausal status prior to enrollment in the study.

    Males who are sexually active and who are partners of women of childbearing potential must agree to use an effective contraception from informed consent obtained to 180 days after last dose administration.

  5. A negative result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
  6. Provide written informed consent prior to undertaking any study-related procedures.
  7. Must not be under any administrative or legal supervision or under institutionalization as per a regulatory or juridical order.

Exclusion criteria

Exclusion Criteria:

  1. Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, musculoskeletal, rheumatological, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness.
  2. Any history or presence of gastrointestinal, hepatic, renal disease that affect drug absorption or metabolism.
  3. Any history or presence of chronic infectious diseases such as tuberculosis (TB) (judged by the Investigator according to QuantiFERON-TB Gold).
  4. Presence or history of drug/food , or anaphylactic reaction, diagnosed and treated by a physician, or have special dietary requirements.
  5. Known hypersensitivity to any component of the IMP formulation.
  6. Any surgery within 1 months prior to the first dose.
  7. Positive result on any of the following tests: virus (HBV), virus (HCV), (HIV), hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBcAb) (for those with positive result on HbcAb, a HBV deoxyribonucleic acid (DNA) test will be performed and those with positive HBV DNA results will be excluded), HCV antibody (HCVAb), anti-human immunodeficiency virus 1 and 2 antibodies.
  8. History or presence of alcohol abuse (defined as alcohol consumption more than 2 units per day 6 months prior to the first dose, 1 unit=360 mL of beer or 45 mL of alcohol 40% and above or 150 mL of wine).
  9. History of drug abuse including narcotic and psychiatric drugs within 1 year prior to screening or a positive drug abuse test result at screening. One repeat is allowed at the discretion of the study doctor in case of false positives.
  10. Regular smoking (defined as more than 5 cigarettes or equivalent per week) within one year prior to the first dose, or unable to stop smoking from 48 hours prior to the first drug administration to the last time point for collecting PK blood samples (Day 11).
  11. Positive alcohol test at screening and check-in on Day -1.
  12. Any consumption of xanthine bases and/or grapefruit or products containing xanthine bases and/or grapefruit within 2 weeks prior to the first dose; or unable to stop consumption of above ingredients during the pharmacokinetic (PK) assessments period (Day 1 to Day 11).
  13. Any consumption of chocolate or caffeine or products containing caffeine within 48hours prior to the first dose; or unable to stop consumption of above ingredients during the PK assessments period (Day1 to Day11).
  14. Any consumption of alcohol or products containing alcohol within 48 hours prior to study site admission (Day -1); or unable to stop consumption of alcohol during the PK assessments period (Day 1-Day 11).
  15. Any drug that inhibits or induces liver drug metabolism (inducers include barbiturates, carbamazepine, rifampicin, phenytoin, , omeprazole, etc.; inhibitors include selective serotonin reuptake inhibitor (SSRI) antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines, etc.) within 30 days prior to the first dose or during the study.
  16. Any prescription medication, within 14 days prior to administration of the first dose, with the exception of hormonal , menopausal hormone replacement therapy or occasional analgesics such as Paracetamol, Ibuprofen and standard daily vitamins etc. in short term at the Investigator's direction.
  17. Made a blood donation of greater than 400 ml within 4 weeks prior to the first dose or during the study.
  18. Any participant who enrolled in or participated in any other clinical study involving an product, or in any other type of medical research within 1 month or within 5 times the elimination t1/2 prior to administration of the first dose.
  19. Any vaccination in the 14 days prior to administration of the first dose.
  20. Any participant who, in the judgment of the Investigator, is likely to be non-compliant during the study, or to be unable to cooperate due to language problems or poor mental development.
  21. Any participant who is the Investigator, research assistant, pharmacist, study coordinator, or other staff thereof directly involved in conducting the study or any person dependent on (employees or immediate family members) the study site, the Investigator or the Sponsor.
  22. Any participant who cannot be contacted in the case of an emergency.
  23. Any participant in whom venous blood collection is difficult.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Hemay005 60 mg

    The participant will receive single administration of Hemay005 tablets at dose of 60 mg on Day 1. Thereafter, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily.

    Drug: Hemay005 60 mg

Interventions

  • The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition. On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9.

    Also known as: Hemay005 treatment group

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AE) following administration of Hemay005 tablets as a measure of safety and tolerability

    Incidence and severity of adverse events as assessed by CTCAE V5.0 by the investigator.

    Time frame: Up to Day 20 after the first dose

  2. Number of participants with abnormal hematology laboratory tests results following administration of Hemay005 tablets as a measure of safety and tolerability

    The safety and tolerability of Hemay005 tablets will be assessed by Clinical laboratory abnormality in hematology assessed by changes from baseline following administration of Hemay005 tablets

    Time frame: Up to Day 20 after the first dose

  3. Number of participants with abnormal chemistry laboratory tests results following administration of Hemay005 tablets as a measure of safety and tolerability

    The safety and tolerability of Hemay005 tablets will be assessed by Clinical laboratory abnormality in clinical chemistry assessed by changes from baseline following administration of Hemay005 tablets

    Time frame: Up to Day 20 after the first dose

  4. Number of participants with abnormal coagulation laboratory tests results following administration of Hemay005 tablets as a measure of safety and tolerability

    The safety and tolerability of Hemay005 tablets will be assessed by Clinical laboratory abnormality in coagulation assessed by changes from baseline following administration of Hemay005 tablets

    Time frame: Up to Day 20 after the first dose

  5. Number of participants with abnormal urinalysis results following administration of Hemay005 tablets as a measure of safety and tolerability

    The safety and tolerability of Hemay005 tablets will be assessed by Clinical laboratory abnormality in urinalysis assessed by changes from baseline following administration of Hemay005 tablets

    Time frame: Up to Day 20 after the first dose

  6. Number of participants with abnormal stool analysis results following administration of Hemay005 tablets as a measure of safety and tolerability

    The safety and tolerability of Hemay005 tablets will be assessed by Clinical laboratory abnormality in stools assessed by changes from baseline following administration of Hemay005 tablets

    Time frame: Up to Day 20 after the first dose

  7. Number of participants with abnormal systolic and diastolic blood pressure following administration of Hemay005 tablets as a measure of safety and tolerability

    The safety and tolerability of Hemay005 tablets will be assessed by changes in Vital signs from baseline measuring blood pressure. Blood pressure is measured by placing the stethoscope over the arm.

    Time frame: Up to Day 20 after the first dose

  8. Number of participants with abnormal heart rate following administration of Hemay005 tablets as a measure of safety and tolerability

    The safety and tolerability of Hemay005 tablets will be assessed by changes in Vital signs from baseline measuring heart rate. Heart Rate is measured by an ECG and respiration rate is counted manually as breaths per minute by the Clinical Unit Assistants.

    Time frame: Up to Day 20 after the first dose

  9. Number of participants with abnormal body temperature following administration of Hemay005 tablets as a measure of safety and tolerability

    The safety and tolerability of Hemay005 tablets will be assessed by changes in Vital signs from baseline measuring body temperature. Body temperature is measured using an oral thermometer.

    Time frame: Up to Day 20 after the first dose

  10. Number of participants with abnormal electrocardiograms readings following administration of Hemay005 tablets as a measure of safety and tolerability

    12-lead ECGs will be obtained during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT duration corrected for heart rate by Fridericia's formula (QTcF intervals) at each timepoint

    Time frame: Up to Day 20 after the first dose

Secondary outcomes

  1. Change from baseline in the maximum plasma concentration (Cmax) following administration of Hemay005 tablets to evaluate the pharmacokinetics (PK) characteristics of Hemay005 tablets

    The PK parameters are assessed by measuring the maximum plasma concentration (Cmax)

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

  2. Change from baseline in time to Cmax (Tmax) following administration of Hemay005 tablets to evaluate the pharmacokinetics (PK) characteristics of Hemay005 tablets

    The PK parameters are assessed by measuring the time to Cmax (Tmax)

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

  3. Area under the curve from time 0 to the last measurable concentration (AUC0-t) to evaluate the Pharmacokinetic (PK) parameters of Hemay005 tablets

    The PK parameters are assessed by measuring the area under the curve from time 0 to the last measurable concentration (AUC0-t)

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

  4. Area under the curve from time 0 extrapolated to infinite time (AUC0-inf) to assess the Pharmacokinetic (PK) parameters of Hemay005 tablets

    The PK parameters are assessed by measuring the area under the curve from time 0 extrapolated to infinite time (AUC0-inf),

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

  5. Change from Baseline in half-life (t1/2) following administration of Hemay005 tablets to evaluate the pharmacokinetics (PK) characteristics of Hemay005 tablets

    The PK parameters are assessed by measuring the half-life (t1/2)

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

  6. Change from Baseline in apparent clearance (CL/F) following administration of Hemay005 tablets to evaluate the pharmacokinetics (PK) characteristics of Hemay005 tablets

    The PK parameters are assessed by measuring the apparent clearance (CL/F)

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

  7. Change from Baseline in apparent volume of distribution (Vz/F) following administration of Hemay005 tablets to evaluate the pharmacokinetics (PK) characteristics of Hemay005 tablets

    The PK parameters are assessed by measuring the apparent volume of distribution (Vz/F)

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

  8. Change from Baseline in serum trough concentration (Ctrough) following administration of Hemay005 tablets to evaluate the pharmacokinetics (PK) characteristics of Hemay005 tablets

    The PK parameters are assessed by measuring the serum trough concentration (Ctrough)

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

  9. Area under the curve extrapolated as a percentage of the total (AUC_%Extrap) to assess the Pharmacokinetic (PK) parameters of Hemay005 tablets

    The PK parameters are assessed by measuring the area under the curve extrapolated as a percentage of the total (AUC_%Extrap)

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

  10. Change from Baseline in mean residence time from the time of dosing to the time of last measurable concentration (MRTlast) to assess the Pharmacokinetic (PK) parameters of Hemay005 tablets

    The PK parameters are assessed by measuring mean residence time from the time of dosing to the time of last measurable concentration (MRTlast)

    Time frame: On Day 1 and Day 9, blood samples for PK analysis will be collected within 1 hour pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36 and 48 hours post-dose; during Day 4 to Day 8 in the morning prior to administration.

07

Study locations

1 site
  • Scientia Clinical Research Ltd
    Randwick, New South Wales 2031, Australia
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Aug 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2023
First posted
Jul 12, 2023
StartActual
Jul 17, 2023
Primary completionActual
Aug 8, 2023
CompletionActual
Aug 20, 2023
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05941247
Lead sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Collaborators
Hemay Pharmaceutical PTY. LTD.
Responsible party
Sponsor
First posted
Jul 12, 2023
Start date
Jul 17, 2023
Primary completion
Aug 8, 2023
Completion
Aug 20, 2023
Last update
Mar 1, 2024

Study contacts

Christopher J Argent
principal investigator · Scientia Clinical Research Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemay005

Start the discussion